Momenta Pharmaceuticals Appoints Steven C. Gilman, Ph.D. to Board of Directors
June 23 2016 - 8:00AM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the appointment of Steven C. Gilman,
Ph.D. to its Board of Directors effective June 22, 2016. Dr.
Gilman was most recently Executive Vice President, Research &
Development and Chief Scientific Officer at Cubist Pharmaceuticals,
until its acquisition by Merck & Co. in January 2015.
"Steve brings a strong set of biopharmaceutical
research and development expertise and I am very pleased that he
has decided to join our Board," said Craig Wheeler, President and
CEO, Momenta Pharmaceuticals. “His wealth of experience in building
and leading novel immunology and inflammation drug development
programs will be of significant importance as we work to rapidly
advance our biosimilar and novel autoimmune drug portfolios toward
commercialization.”
Momenta also announced today that Bennett M.
Shapiro, M.D., will no longer serve as a member of Momenta’s Board
of Directors following completion of his term ending on June 22,
2016. Dr. Shapiro was a member of the Board of Directors
since 2003, serving on the science, compensation, and nominating
and corporate governance committees.
"I'd like to thank Ben for his many years of
invaluable support in building Momenta into the company it is today
with two complex generic products on the market and a robust
portfolio of biosimilar and novel drug candidates. We wish him well
in his future endeavors," continued Mr. Wheeler.
Dr. Gilman currently serves as the Executive
Chairman and interim CEO of ContraFect Corporation (NASDAQ:CFRX)
and as a member of the board of directors of Vericel (NASDAQ:VCEL),
SCYNEXIS (NASDAQ:SCYX) and Keryx (NASDAQ:KERX). He also serves as a
member of the board of directors of the Northeastern University
Drug Discovery Advisory Board, the Massachusetts Biotechnology
Association and the Penn State University Biotechnology Advisory
Board.
Prior to joining Cubist, Dr. Gilman served as
Chairman of the Board of Directors and CEO of ActivBiotics, a
privately held biopharmaceutical company. Previously, Dr. Gilman
worked at Millennium Pharmaceuticals, Inc., where he held a number
of senior leadership roles including Vice President and General
Manager of the Inflammation Franchise. Prior to Millennium, he was
Group Director at Pfizer Central Research, where he was responsible
for drug discovery of novel antibacterial agents as well as several
other therapeutic areas. Dr. Gilman has also held scientific,
business, and academic appointments at Wyeth, Cytogen Corporation,
Temple University School of Medicine, and Connecticut College. Dr.
Gilman received his Ph.D. and M.S. degrees in microbiology from
Pennsylvania State University, his post-doctoral training at
Scripps Clinic and Research Foundation, and received a B.A. in
microbiology from Miami University of Ohio.
About Momenta
Momenta Pharmaceuticals is a biotechnology
company specializing in the detailed structural analysis of complex
drugs and is headquartered in Cambridge, MA. Momenta is
applying its technology to the development of generic versions of
complex drugs, biosimilar and potentially interchangeable
biologics, and to the discovery and development of novel
therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does
not form a part of this press release.
Our logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
Forward Looking Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements about Dr. Gilman
benefitting the Company; advancing our product pipeline; and
bringing multiple products to market in the coming years.
Forward-looking statements may be identified by words such as
"will," "work" and other similar words or expressions, or the
negative of these words or similar words or expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors, including those referred to under
the section "Risk Factors" in the Company's Quarterly Report on
Form 10-Q for the month ended March 31, 2016, filed with the
Securities and Exchange Commission, as well as other documents that
may be filed by the Company from time to time with the Securities
and Exchange Commission. As a result of such risks, uncertainties
and factors, the Company's actual results may differ materially
from any future results, performance or achievements discussed in
or implied by the forward-looking statements contained herein. The
Company is providing the information in this press release as of
this date and assumes no obligations to update the information
included in this press release or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Sep 2023 to Sep 2024